ClinicalTrials.gg
CompletedNCT01355497Updated Nov 9, 2020Results posted

Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum

A Phase 3 interventional study of GTx-024 and placebo in Muscle Wasting and Non-Small Cell Lung Cancer, sponsored by GTx. Completed at 30 sites in United States. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2020-11-09.

Sponsored by GTx · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 115 studies in Muscular Atrophy with a site in United States — 15 open to participants now, 26 under way, 2 of them phase 3. Muscular Atrophy · United States.

Enrollment
2nd of 105
330 · median 40
Started
2011
with 5 others
Phase 3
10 of 115
none open now
Registered
16th of 115
by date
Lead sponsor
3 of 115
GTx

Among the 115 studies in Muscular Atrophy with a site in United States, this one is the 2nd largest by enrollment of the 105 interventional ones that give a count, is one of 6 that started in 2011, is one of 10 in phase 3, and was the 16th registered.

Muscular Atrophy

413 studies on the registry are indexed under Muscular Atrophy; 77 are open to participants now.

Browse Muscular Atrophy studies →

Open to participants now

15 of the 115 studies in Muscular Atrophy with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 52 Muscular Atrophy studies recruiting now, 25 (48%) set no upper age limit and 13 (25%) stop at 75 or younger; 4 take children under 18; 17 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies in Muscular Atrophy with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine if the investigational drug GTx-024 can help patients with non small cell lung cancer increase physical function and maintain or gain muscle.

Read the detailed description

This is a randomized, double blind, placebo controlled, multicenter, multinational efficacy and safety study in subjects with non small cell lung cancer. Subjects will be evenly randomized to placebo or GTx-024 prior to initiation of first line chemotherapy. The primary efficacy analysis will be based on total Lean Body Mass (LBM) and physical function.

03

Conditions studied

  • Muscle Wasting
  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • give voluntary, signed in accordance with institutional policies
  • be non-obese as defined as (BMI)\< or = 32 and weight \< 300 pounds (\< 136 kg)
  • have been diagnosed with Stage III or IV NSCLC
  • be prior to chemotherapy
  • planned first line chemotherapy regimen is platinum plus gemcitabine only or platinum plus vinorelbine only or platinum plus pemetrexed only
  • if surgery is part of the cancer treatment, screening for this study should be conducted at least 4 weeks (28 days) after surgery
  • of > 6 months
  • score \< or = 1
  • serum creatinine \< or = 2.0 mg/dL
  • MALES - age > or = 30 years
    • FEMALES - age >or=30 years and clinically confirmed as .Subjects must have undergone the onset of spontaneous or surgical menopause prior to the start of this study. Spontaneous menopause is defined as the natural cessation of ovarian function as indicated by being amenorrheic for at least 12 months. If the subject has been amenorrheic for >or=6 months but \<12 months they must have a serum FSH concentration of >or=50 mIU/mL and an estradiol concentration of \<or=25 pg/mL. Surgical menopause is defined as bilateral oophorectomy.
  • MALES - subjects must agree to use a double barrier method of during the study and for 3 months after study completion. This may include the following: condom + spermicide or condom + oral hormonal contraception
  • MALES - have a serum PSA of \< or = 4.0 ng/mL or a negative prostate (no prostate cancer) within 6 months of evaluation

Exclusion criteria

Exclusion Criteria:

  • Have, in the judgment of the Investigator, a concurrent illness or psychological, familial, sociological, geographical or other concomitant condition that would not permit adequate follow-up and compliance with the study protocol
  • Have /SGOT or AST/SGPT above 1.5 times the (ULN) without evidence of liver and above 5 times the ULN in subjects with evidence of liver metastases
  • have alkaline phosphatase greater than 3 times ULN and/or total levels above 2 mg/dL at baseline
  • have biologic agents or kinase inhibitors as part of their chemotherapy regimen including, but not limited to bevacizumab (Avastin), gefitinib (Nexavar) and erlotinib (Tarceva)
  • cardiovascular: uncontrolled hypertension, congestive heart failure or angina
  • Pulmonary: Stage 4 (COPD)
  • positive screen for consisting of HBsAg (Hepatitis B Surface Antigen), unless subject was diagnosed > 10 years prior to enrollment and no evidence of active liver disease
  • currently taking testosterone, oxandrolone (Oxandrin), testosterone-like agents (such as dehydroepiandrosterone (DHEA), androstenedione, and other androgenic compounds including herbals), or antiandrogens; previous therapy with testosterone and testosterone-like agents is acceptable with a 30 day washout (if previous testosterone therapy was long term depot within the past 6 months, the site should contact the medical monitor for this study to determine appropriate )
  • currently taking megestrol acetate (Megace), dronabinol (Marinol), medical marijuana (medical cannabis) or any prescription medication intended to increase appetite or treat unintentional weight loss
  • have a baseline stair climb time >or=30 seconds (mean of two stair climbs)
  • have active cancer, other than NSCLC or non-melanoma carcinoma of the skin, within the previous two years.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
330 participants (actual)

Study arms

  • Experimental
    GTx-024 3mg once daily

    subjects will be randomized to receive GTx-024 3mg sofgel capsule once daily for the duration of the trial

    Drug: GTx-024

  • Placebo comparator
    placebo

    subjects will be randomized to receive matching placebo once daily for the duration of the trial

    Drug: placebo

Interventions

  • subjects will be randomized to receive GTx-024 3mg softgel for the duration of the trial.

    Also known as: enobosarm, ostarine

  • Drugplacebo

    subject will receive matching placebo for the duration of the trial

06

What researchers measure

Primary outcomes

  1. Physical Function

    Measure is the percentage of subjects at day 84 with stair climb power change \>=10% from their baseline value.

    Time frame: Day 84

  2. Lean Body Mass

    Measure is the percentage of subjects at day 84 with lean body mass change \>=0% from their baseline value.

    Time frame: Day 84

07

Results

Posted Nov 9, 2020

Participant flow

Participant flow — Overall Study
MilestoneGTx-024 3mg Once DailyPlacebo
Started165165
Completed99102
Not completed6663
Withdrew: Death1918
Withdrew: Lost to follow-up30
Withdrew: Protocol violation01
Withdrew: Other-not provided94
Withdrew: Withdrawal by subject1220
Withdrew: Noncompliance12
Withdrew: Progressive disease118
Withdrew: Adverse event1110

Outcome measures

PrimaryPhysical Function

Measure is the percentage of subjects at day 84 with stair climb power change \>=10% from their baseline value.

Time frame:
Day 84
Reported as:
Number · percentage of subjects
Physical Function
percentage of subjectsGTx-024Placebo
Physical Function19.5 (13.6 to 26.5)24.8 (18.4 to 32.3)
PrimaryLean Body Mass

Measure is the percentage of subjects at day 84 with lean body mass change \>=0% from their baseline value.

Time frame:
Day 84
Reported as:
Number · percentage of subjects
Lean Body Mass
percentage of subjectsGTx-024Placebo
Lean Body Mass46.5 (38.6 to 54.6)37.9 (30.4 to 45.9)

Adverse events

Collected over 1 year, 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GTx-024 3mg Once Daily—109/165 (66.1%)149/165 (90.3%)
Placebo Once Daily—113/165 (68.5%)157/165 (95.2%)
Most frequent serious events
Showing 10 of 95
Most frequent serious events
EventGTx-024 3mg Once DailyPlacebo Once Daily
Disease ProgressionGeneral disorders18/16526/165
AnaemiaBlood and lymphatic system disorders12/1659/165
NeutropeniaBlood and lymphatic system disorders10/16510/165
ThrombocytopeniaBlood and lymphatic system disorders8/1655/165
Cerebrovascular AccidentNervous system disorders2/1656/165
LeukopeniaBlood and lymphatic system disorders5/1652/165
Febrile NeutropeniaBlood and lymphatic system disorders5/1651/165
PneumoniaInfections and infestations4/1655/165
Pulmonary HaemorrhageRespiratory, thoracic and mediastinal disorders4/1652/165
DiarrhoeaGastrointestinal disorders3/1651/165
Most frequent other events
Showing 10 of 25
Most frequent other events
EventGTx-024 3mg Once DailyPlacebo Once Daily
AnemiaBlood and lymphatic system disorders84/16579/165
NauseaGastrointestinal disorders74/16573/165
NeutropeniaBlood and lymphatic system disorders51/16556/165
VomitingGastrointestinal disorders45/16548/165
Decreased AppetiteMetabolism and nutrition disorders32/16528/165
ThrombocytopeniaBlood and lymphatic system disorders31/16529/165
Disease ProgressionGeneral disorders29/16531/165
FatigueGeneral disorders26/16529/165
LeukopeniaBlood and lymphatic system disorders26/16528/165
AstheniaGeneral disorders25/16527/165

Baseline characteristics

Subjects included in the Full Analysis Set

Age, Continuous
Age, Continuous(years)GTx-024PlaceboTotal
Median60.0 (41 to 79)62.0 (40 to 81)61.0 (40 to 81)
Sex: Female, Male
Sex: Female, Male(Participants)GTx-024PlaceboTotal
Female454893
Male114113227
08

Study locations

30 sites
  • GTx Investigative Site
    Birmingham, Alabama 35211, United States
  • GTx Investigative Site
    Scottsdale, Arizona 85255, United States
  • GTx Investigative Site
    La Jolla, California 92093, United States
  • GTx Investigative Site
    Long Beach, California 90813, United States
  • GTx Investigative Site
    Miami, Florida 33133, United States
  • GTx Investigative Site
    Orange City, Florida 32763, United States
  • GTx Investigative Site
    Tampa, Florida 33612, United States
  • GTx Investigative Site
    Decatur, Illinois 62526, United States
  • GTx Investigative Site
    Peoria, Illinois 61615, United States
  • GTx Investigative Site
    Skokie, Illinois 60076, United States
  • GTx Investigative Site
    Goshen, Indiana 46526, United States
  • GTx Investigative Site
    Indianapolis, Indiana 46260, United States
  • GTx Investigative Site
    Ashland, Kentucky 41101, United States
  • GTx Investigative Site
    Concord, Massachusetts 01742, United States
  • GTx Investigative Site
    Saint Clair Shores, Michigan 48081, United States
  • GTx Investigative Site
    Tupelo, Mississippi 38801, United States
  • GTx Investigative Site
    Great Falls, Montana 59405, United States
  • GTx Investigative Site
    Rochester, New York 14642, United States
  • GTx Investigative Site
    Burlington, North Carolina 27215, United States
  • GTx Investigator
    Flat Rock, North Carolina 28731, United States
  • GTx Investigative Site
    Wilmington, North Carolina 28401, United States
  • GTx Investigative Site
    Winston-Salem, North Carolina 27103, United States
  • GTx Investigative Site
    Canfield, Ohio 44406, United States
  • Gabrail Cancer Center
    Canton, Ohio 44718, United States
  • GTx Investigative Site
    Sandusky, Ohio 44870, United States
  • GTx Investigative Site
    Portland, Oregon 97213, United States
  • GTx Investigative Site
    Lancaster, Pennsylvania 17604, United States
  • GTx Investigative Site
    Spartanburg, South Carolina 29303, United States
  • GTx Investigative Site
    Nashville, Tennessee 37203, United States
  • GTx Investigative Site
    Round Rock, Texas 78665, United States
09

References and documents

Publications

  • Crawford J, Prado CM, Johnston MA, Gralla RJ, Taylor RP, Hancock ML, Dalton JT. Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials). Curr Oncol Rep. 2016 Jun;18(6):37. doi: 10.1007/s11912-016-0522-0. PubMed 27138015 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of May 2013 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2020, 7 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2011
First posted
May 18, 2011
Start
Jul 2011
Primary completionActual
May 2013
CompletionActual
Jun 2014
Results first posted
Nov 9, 2020
Last update
Nov 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01355497
Lead sponsor
GTx
Responsible party
Sponsor
First posted
May 18, 2011
Start date
Jul 2011
Primary completion
May 2013
Completion
Jun 2014
Results posted
Nov 9, 2020
Last update
Nov 9, 2020

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ostarine

Start the discussion